Johannes Oldenburg

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

E. Havrdová, X. Mariette, S. Lacroix-Desmazes, 2015, Clinical and experimental immunology.

Inhibitors in haemophilia: pathophysiology

S. Lacroix-Desmazes, J. Oldenburg, J. Saint-Remy, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Novel products for haemostasis – current status

J. Oldenburg, T. Albert, Johannes Oldenburg, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia care then, now and in the future

G. Lemm, Johannes Oldenburg, Gerry Dolan, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor

C. Négrier, E. Gomperts, J. Oldenburg, 2006 .

In silico calculated affinity of FVIII‐derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene

S. Kaveri, S. Lacroix-Desmazes, J. Oldenburg, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.